Fibroblast growth factor-2 mediates pressure-induced hypertrophic response

Jo El J. Schultz, Sandra A. Witt, Michelle L. Nieman, Peter J. Reiser, Sandra J. Engle, Ming Zhou, Sharon A. Pawlowski, John N. Lorenz, Thomas R. Kimball, Thomas Doetschman

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

In vitro, fibroblast growth factor-2 (FGF2) has been implicated in cardiomyocyte growth and reexpression of fetal contractile genes, both markers of hypertrophy. However, its in vivo role in cardiac hypertrophy during pressure overload is not well characterized. Mice with or without FGF2 (Fgf2(+/+) and Fgf2(-/-), respectively) were subjected to transverse aortic coarctation (AC). Left ventricular (LV) mass and wall thickness were assessed by echocardiography preoperatively and once a week postoperatively for 10 weeks. In vivo LV function during dobutamine stimulation, cardiomyocyte Cross-sectional area, and recapitulation of fetal cardiac genes were also measured. AC Fgf2(-/-) mice develop significantly less hypertrophy (4-24% increase) compared with ac Fgf2(+/+) mice (41-52% increase). Cardiomyocyte cross, sectional area is significantly reduced in AC Fgf2(-/-) mice. Noncoarcted (NC) and AC Fgf2(-/-) mice have similar β-adrenergic responses, but those of AC Fgf2(+/+) mice are blunted. A lack of mitotic growth in both AC Fgf2(+/+) and Fgf2(-/-) hearts indicates a hypertrophic response of cardiomyocytes. Consequently, FGF2 plays a major role in cardiac hypertrophy. Comparison of α- and β-cardiac myosin heavy chain mRNA and protein levels in NC and AC Fgf2(+/+) and Fgf2(-/-)mice indicates that myosin heavy chain composition depends on hemodynamic stress rather than on FGF2 or hypertrophy, and that isoform switching is transcriptionally, not posttranscriptionally, regulated.

Original languageEnglish (US)
Pages (from-to)709-719
Number of pages11
JournalJournal of Clinical Investigation
Volume104
Issue number6
DOIs
StatePublished - Jan 1 1999

Fingerprint

Aortic Coarctation
Fibroblast Growth Factor 2
Pressure
Cardiac Myocytes
Hypertrophy
Myosin Heavy Chains
Cardiomegaly
Cardiac Myosins
Dobutamine
Fetal Development
Left Ventricular Function
Adrenergic Agents
Genes
Echocardiography
Protein Isoforms
Hemodynamics
Messenger RNA
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Schultz, J. E. J., Witt, S. A., Nieman, M. L., Reiser, P. J., Engle, S. J., Zhou, M., ... Doetschman, T. (1999). Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. Journal of Clinical Investigation, 104(6), 709-719. https://doi.org/10.1172/JCI7315

Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. / Schultz, Jo El J.; Witt, Sandra A.; Nieman, Michelle L.; Reiser, Peter J.; Engle, Sandra J.; Zhou, Ming; Pawlowski, Sharon A.; Lorenz, John N.; Kimball, Thomas R.; Doetschman, Thomas.

In: Journal of Clinical Investigation, Vol. 104, No. 6, 01.01.1999, p. 709-719.

Research output: Contribution to journalArticle

Schultz, JEJ, Witt, SA, Nieman, ML, Reiser, PJ, Engle, SJ, Zhou, M, Pawlowski, SA, Lorenz, JN, Kimball, TR & Doetschman, T 1999, 'Fibroblast growth factor-2 mediates pressure-induced hypertrophic response', Journal of Clinical Investigation, vol. 104, no. 6, pp. 709-719. https://doi.org/10.1172/JCI7315
Schultz, Jo El J. ; Witt, Sandra A. ; Nieman, Michelle L. ; Reiser, Peter J. ; Engle, Sandra J. ; Zhou, Ming ; Pawlowski, Sharon A. ; Lorenz, John N. ; Kimball, Thomas R. ; Doetschman, Thomas. / Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. In: Journal of Clinical Investigation. 1999 ; Vol. 104, No. 6. pp. 709-719.
@article{9b55a6b100ae4600b59facfc37472e75,
title = "Fibroblast growth factor-2 mediates pressure-induced hypertrophic response",
abstract = "In vitro, fibroblast growth factor-2 (FGF2) has been implicated in cardiomyocyte growth and reexpression of fetal contractile genes, both markers of hypertrophy. However, its in vivo role in cardiac hypertrophy during pressure overload is not well characterized. Mice with or without FGF2 (Fgf2(+/+) and Fgf2(-/-), respectively) were subjected to transverse aortic coarctation (AC). Left ventricular (LV) mass and wall thickness were assessed by echocardiography preoperatively and once a week postoperatively for 10 weeks. In vivo LV function during dobutamine stimulation, cardiomyocyte Cross-sectional area, and recapitulation of fetal cardiac genes were also measured. AC Fgf2(-/-) mice develop significantly less hypertrophy (4-24{\%} increase) compared with ac Fgf2(+/+) mice (41-52{\%} increase). Cardiomyocyte cross, sectional area is significantly reduced in AC Fgf2(-/-) mice. Noncoarcted (NC) and AC Fgf2(-/-) mice have similar β-adrenergic responses, but those of AC Fgf2(+/+) mice are blunted. A lack of mitotic growth in both AC Fgf2(+/+) and Fgf2(-/-) hearts indicates a hypertrophic response of cardiomyocytes. Consequently, FGF2 plays a major role in cardiac hypertrophy. Comparison of α- and β-cardiac myosin heavy chain mRNA and protein levels in NC and AC Fgf2(+/+) and Fgf2(-/-)mice indicates that myosin heavy chain composition depends on hemodynamic stress rather than on FGF2 or hypertrophy, and that isoform switching is transcriptionally, not posttranscriptionally, regulated.",
author = "Schultz, {Jo El J.} and Witt, {Sandra A.} and Nieman, {Michelle L.} and Reiser, {Peter J.} and Engle, {Sandra J.} and Ming Zhou and Pawlowski, {Sharon A.} and Lorenz, {John N.} and Kimball, {Thomas R.} and Thomas Doetschman",
year = "1999",
month = "1",
day = "1",
doi = "10.1172/JCI7315",
language = "English (US)",
volume = "104",
pages = "709--719",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - Fibroblast growth factor-2 mediates pressure-induced hypertrophic response

AU - Schultz, Jo El J.

AU - Witt, Sandra A.

AU - Nieman, Michelle L.

AU - Reiser, Peter J.

AU - Engle, Sandra J.

AU - Zhou, Ming

AU - Pawlowski, Sharon A.

AU - Lorenz, John N.

AU - Kimball, Thomas R.

AU - Doetschman, Thomas

PY - 1999/1/1

Y1 - 1999/1/1

N2 - In vitro, fibroblast growth factor-2 (FGF2) has been implicated in cardiomyocyte growth and reexpression of fetal contractile genes, both markers of hypertrophy. However, its in vivo role in cardiac hypertrophy during pressure overload is not well characterized. Mice with or without FGF2 (Fgf2(+/+) and Fgf2(-/-), respectively) were subjected to transverse aortic coarctation (AC). Left ventricular (LV) mass and wall thickness were assessed by echocardiography preoperatively and once a week postoperatively for 10 weeks. In vivo LV function during dobutamine stimulation, cardiomyocyte Cross-sectional area, and recapitulation of fetal cardiac genes were also measured. AC Fgf2(-/-) mice develop significantly less hypertrophy (4-24% increase) compared with ac Fgf2(+/+) mice (41-52% increase). Cardiomyocyte cross, sectional area is significantly reduced in AC Fgf2(-/-) mice. Noncoarcted (NC) and AC Fgf2(-/-) mice have similar β-adrenergic responses, but those of AC Fgf2(+/+) mice are blunted. A lack of mitotic growth in both AC Fgf2(+/+) and Fgf2(-/-) hearts indicates a hypertrophic response of cardiomyocytes. Consequently, FGF2 plays a major role in cardiac hypertrophy. Comparison of α- and β-cardiac myosin heavy chain mRNA and protein levels in NC and AC Fgf2(+/+) and Fgf2(-/-)mice indicates that myosin heavy chain composition depends on hemodynamic stress rather than on FGF2 or hypertrophy, and that isoform switching is transcriptionally, not posttranscriptionally, regulated.

AB - In vitro, fibroblast growth factor-2 (FGF2) has been implicated in cardiomyocyte growth and reexpression of fetal contractile genes, both markers of hypertrophy. However, its in vivo role in cardiac hypertrophy during pressure overload is not well characterized. Mice with or without FGF2 (Fgf2(+/+) and Fgf2(-/-), respectively) were subjected to transverse aortic coarctation (AC). Left ventricular (LV) mass and wall thickness were assessed by echocardiography preoperatively and once a week postoperatively for 10 weeks. In vivo LV function during dobutamine stimulation, cardiomyocyte Cross-sectional area, and recapitulation of fetal cardiac genes were also measured. AC Fgf2(-/-) mice develop significantly less hypertrophy (4-24% increase) compared with ac Fgf2(+/+) mice (41-52% increase). Cardiomyocyte cross, sectional area is significantly reduced in AC Fgf2(-/-) mice. Noncoarcted (NC) and AC Fgf2(-/-) mice have similar β-adrenergic responses, but those of AC Fgf2(+/+) mice are blunted. A lack of mitotic growth in both AC Fgf2(+/+) and Fgf2(-/-) hearts indicates a hypertrophic response of cardiomyocytes. Consequently, FGF2 plays a major role in cardiac hypertrophy. Comparison of α- and β-cardiac myosin heavy chain mRNA and protein levels in NC and AC Fgf2(+/+) and Fgf2(-/-)mice indicates that myosin heavy chain composition depends on hemodynamic stress rather than on FGF2 or hypertrophy, and that isoform switching is transcriptionally, not posttranscriptionally, regulated.

UR - http://www.scopus.com/inward/record.url?scp=0032748024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032748024&partnerID=8YFLogxK

U2 - 10.1172/JCI7315

DO - 10.1172/JCI7315

M3 - Article

VL - 104

SP - 709

EP - 719

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 6

ER -